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The prevalence of Hepatitis C virus (HCV), one of the causative agents of viral hepatitis was investiga-
ted. One hundred and sixty-seven (167) blood samples from donors which were sero-negative to 
hepatitis B virus markers were screened for presence of HCV IgM antibodies using a third generation 
ELISA kit. Out of the 167 sample tested 14 (8.4%) were positive for anti-HCV with the highest prevalence 
rate recorded in the age group 30-39 years. There is no statistically significant association between the 
sex and the rate of HCV infection (p0.05).  
 





Hepatitis is an inflammatory condition of the liver while 
viral hepatitis is a conventional term used to denote 
hepatitis caused by the hepatotrophic viruses (hepatitis 
A-G). The disease presents a serious public health 
problem in developing countries like Nigeria even in the 
world at large, affecting over 300 million people (Fenner 
and White, 1994). Hepatitis C virus (HCV), one of the 
agent of the disease in question, is a single stranded, 
enveloped, negative sense RNA virus with genomic size 
approximately 9.4 kb (Ogata et al., 1991). HCV, a 
member of flavivirus have been discovered to play a 
primary role in post transfusion hepatitis, proclivity to 
establish long standing persistent infections, association 
with chronic cirrhosis and hepatocellular carcinoma 
(Stanley and Edwin, 1995; Coursaget et al., 1990). It is 
transmitted via blood and blood product, parenterally and 
by sexual contact (Alfredo et al., 1990). The endemicity in 
the developing parts of the world is high with majority of 
people being seropositive, with most becoming infected 
at birth or in early childhood. In Nigeria, the prevalence 
rate of HCV varies between 5.8-12.3% (Halim and Ajayi, 
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Report has shown that viral hepatitis is endemic in 
Africa (Oon, 1984). Hepatitis infection is on the increase 
in the society despite the routine screening for Hepatitis B 
virus (HBV) in blood for transfusion (Fenner and White, 
1994). Perhaps, this problem may be due to HCV as 
emphasis are being placed only on HBV which is just one 
of the several agents of the disease as facility for their 
screening are unavailable and very expensive. Absence 
of facilities necessary for proper blood selection may 
mean that people receiving blood transfusion in the 
hospitals are exposed to various hazards. Hence, this 
work is designed to carry out investigation on the 
prevalence of HCV among HBV sero-negative blood 








A total of one hundred and sixty seven (167) blood samples from 
commercial donors aged between 20–59 years in Lagos Island, 




Sample collection, processing and analysis 
 
Five milliliter of peripheral blood samples were collected by venous  




Table 1. Age and sex distribution of hepatitis C virus among blood donors. 
 
Sex distribution Age 
Group  
No. of patients 
(%) screened Male (%) Female (%) 
No. of positive 
patients  
No. of negative 
patients  
10 – 19  2  (1.20) 2  (100.00) 0 (0.00) 0 (0.00) 2 (100.00) 
20 – 29  48 (28.74) 45 (93.75) 3 (6.25) 1 (2.08) 47 (97.92) 
30 – 39  82 (49.10) 80 (97.56) 2  (2.44) 8  (9.76) 74 (90.24) 
40 – 49  29 (17.37) 28 (96.55) 1  (3.45) 4 (13.79) 25 (86.21) 




Table 2. The incidence of HCV with sex among blood donors. 
 
Sex  Positive (%) Negative (%) Total (%) 
Male  13 (8.13) 147 (91.87) 160 (95.81) 
Female  1 (14.29) 6 (85.71) 7 (4.19) 
Total  14 (8.38) 153 (91.62) 167 (100) 
 




puncture using sterile syringes and needles. The blood samples 
were transferred into sterile universal bottles. Serum was extracted 
by centrifugation of blood specimens at 3000 rpm for 10 min and 
stored frozen at -20°C until analyzed. The serum samples were 
coded and the kits were brought to room temperature after which 
screening for anti HCV (IgM) using third generation ELISA kit 
(Monolisa antiHCV plus). The serum samples were added to the 
wells of microtiter plate which were pre-coated with HCV antigen. 
After incubation the wells were aspirated and washed with washing 
solution after which conjugate solution (horse radish peroxidase) 
was added. The presence of antibody to HCV was exhibited by the 
resulting enzyme activity on tetra-meltyl benzidine (TMB) measured 
at 450 nm. Samples were considered positive if the OD value is 
equal or greater than 0.5. 
 
 
RESULTS AND DISCUSSION  
 
Out of the total 167 samples screened, IgM antibodies to 
HCV were found present in 14 (8.4%) patients of which 
13 (92.8%) were males and 1 (3.4%) was a female 
(Table 1). The highest prevalence rate was recorded in 
age group 30 – 39 years. There is no statistical significant 
association between the gender and HCV infections 
(Table 2). The prevalence rate (8.4%) of HCV is high 
compared to the previous studies which reported 6% 
among blood donors (Bojuwoye, 1997). Age group 30–39 
years recorded the highest positive rate with 8 (9.76%) 
being positive among 82 patients. This indirectly revealed 
the sexually active group of the population hence, 
showing probably the mode of transmission of the virus. 
It is also clear from this work that the transfusion of 
blood not screened for hepatitis C virus serve as means 
of acquiring the virus which in turn leads to hepatitis 
infection, as some HBV sero-negative donors are positive 
to HCV in this present study.  Thus, this poses a high risk 
on patients requiring organ transplant and sicklers among 
others who often require blood transfusion during 
operation and crisis, respectively.  
The ever-increasing frequency of anaemia, haemorrh-
age, severe and multiple road accident, complicated 
pregnancies and so on has created an overwhelming 
demand for efficient blood transfusion services in this part 
of the world, and transfusion of blood and blood product 
in clinical practice has become an everyday affairs. It is 
therefore imperative that government should make poli-
cies to increase the quality of blood being transfused in 
our nation hospitals by including HCV among the blood 
pathogens routinely screened for in blood meant for 
transfusion. HCV is endemic in our environment; there-
fore there is also need for the development of vaccines 
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